Literature DB >> 18391760

Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale.

Anjum S Kaka1, Aaron E Foster, Heidi L Weiss, Cliona M Rooney, Ann M Leen.   

Abstract

Effective dendritic cell (DC) function depends on sufficient expression of antigen and costimulatory molecules, and secretion of interleukin (IL)-12. We sought to augment DC stimulatory capacity by optimizing DC phenotype and IL-12 production. DCs, obtained by CD14-selection, were matured using 8 different cytokine cocktails, and expression of costimulatory/major histocompatibility complex molecules and IL-12 production at the end of maturation was assessed. DC stimulatory capacity was determined after pulsing with immunogenic adenoviral CD8 peptide epitopes or after transduction with an Ad5f35-null vector. Resultant T-cell cultures were analyzed using pentamer and interferon-gamma enzyme-linked immunosorbent spot assays. On the basis of DC expression of maturation markers and IL-12 production, we defined prototype "minimal" [tumor necrosis factor-alpha (TNF-alpha), prostaglandin E2], "standard" (IL-1, IL-6, TNF-alpha, prostaglandin E2), and "optimal" (IL-1, IL-6, TNF-alpha, interferon-alpha, CD40 ligand) DC cocktails. Optimal DCs were functionally superior when pulsed with CD8 peptides, but when transduced with Ad5f35, functioned poorly as antigen-presenting cells. We investigated the mechanisms underlying this discrepancy and suggest that prolonged stimulation with potent cytokines (optimal cocktail) in combination with adenoviral transduction alters the kinetics of DC maturation such that the DCs are functionally exhausted by the traditional 48-hour maturation time point. Shortening the DC maturation period posttransduction restored optimal DC stimulatory capacity. Thus, maturation stimuli and viral transduction affects DC phenotype, IL-12 producing capacity, and kinetics of maturation, and all must be considered before designing protocols to generate the optimal DC for cytotoxic T lymphocyte generation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391760      PMCID: PMC2744357          DOI: 10.1097/CJI.0b013e318165f5d2

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  29 in total

1.  Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.

Authors:  Ann M Leen; Uluhan Sili; Barbara Savoldo; Alan M Jewell; Pedro A Piedra; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

2.  Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.

Authors:  Uluhan Sili; M Helen Huls; Alan R Davis; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Immunother       Date:  2003 May-Jun       Impact factor: 4.456

Review 3.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

4.  Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells.

Authors:  Ann Leen; Maheshika Ratnayake; Aaron Foster; Kenneth Heym; Nabil Ahmed; Cliona M Rooney; Stephen Gottschalk
Journal:  J Immunother       Date:  2007-01       Impact factor: 4.456

5.  Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates.

Authors:  Michael P Seiler; Stephen Gottschalk; Vincenzo Cerullo; Maheshika Ratnayake; Viraj P Mane; Christian Clarke; Donna J Palmer; Philip Ng; Cliona M Rooney; Brendan Lee
Journal:  Mol Ther       Date:  2007-02       Impact factor: 11.454

6.  Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Authors:  Stephen Gottschalk; Oliver L Edwards; Uluhan Sili; M Helen Huls; Tatiana Goltsova; Alan R Davis; Helen E Heslop; Cliona M Rooney
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

7.  Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy.

Authors:  Peng H Tan; Sven C Beutelspacher; Shao-An Xue; Yao-He Wang; Peter Mitchell; James C McAlister; D Frank P Larkin; Myra O McClure; Hans J Stauss; Mary A Ritter; Giovanna Lombardi; Andrew J T George
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

8.  Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

Authors:  Andreas Mackensen; Norbert Meidenbauer; Sandra Vogl; Monika Laumer; Jana Berger; Reinhard Andreesen
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

9.  The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Authors:  Catherine M Bollard; Karin C M Straathof; M Helen Huls; Alan Leen; Kristine Lacuesta; Alan Davis; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Immunother       Date:  2004 Jul-Aug       Impact factor: 4.456

10.  Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Authors:  Catherine M Bollard; Stephen Gottschalk; Ann M Leen; Heidi Weiss; Karin C Straathof; George Carrum; Mariam Khalil; Meng-fen Wu; M Helen Huls; Chung-Che Chang; M Victoria Gresik; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

View more
  19 in total

1.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

Review 2.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

3.  IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.

Authors:  Meghan E Turnis; Xiao-Tong Song; Adham Bear; Aaron E Foster; Stephen Gottschalk; Malcolm K Brenner; Si-Yi Chen; Cliona M Rooney
Journal:  J Immunol       Date:  2010-09-03       Impact factor: 5.422

4.  A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells.

Authors:  Yongjun Wang; Shengyu Wang; Yuan Ding; Yanhua Ye; Yingyi Xu; Huixiang He; Qiaozhen Li; Yanjun Mi; Chunhua Guo; Zhicai Lin; Tao Liu; Yaya Zhang; Yuqiang Chen; Jianghua Yan
Journal:  Clin Vaccine Immunol       Date:  2013-07-24

5.  Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.

Authors:  Kiyonori Tanoue; Amanda Rosewell Shaw; Norihiro Watanabe; Caroline Porter; Bhakti Rana; Stephen Gottschalk; Malcolm Brenner; Masataka Suzuki
Journal:  Cancer Res       Date:  2017-02-24       Impact factor: 12.701

6.  Inhibition of renalase drives tumour rejection by promoting T cell activation.

Authors:  Xiaojia Guo; Shlomit Jessel; Rihao Qu; Yuval Kluger; Tian-Min Chen; Lindsay Hollander; Robert Safirstein; Bryce Nelson; Charles Cha; Marcus Bosenberg; Lucia B Jilaveanu; David Rimm; Carla V Rothlin; Harriet M Kluger; Gary V Desir
Journal:  Eur J Cancer       Date:  2022-02-24       Impact factor: 9.162

7.  Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.

Authors:  Nataša Obermajer; Julie Urban; Eva Wieckowski; Ravikumar Muthuswamy; Roshni Ravindranathan; David L Bartlett; Pawel Kalinski
Journal:  Nat Protoc       Date:  2018-01-18       Impact factor: 13.491

8.  AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC.

Authors:  Chang-Xuan You; Min Shi; Yong Liu; Maohua Cao; Rongcheng Luo; Paul L Hermonat
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

9.  Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity.

Authors:  Albert C C Lin; Dilan Dissanayake; Salim Dhanji; Alisha R Elford; Pamela S Ohashi
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

10.  Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Ulrike Gerdemann; Juan F Vera; Cliona M Rooney; Ann M Leen
Journal:  J Vis Exp       Date:  2011-05-27       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.